| Clinical applications of textural analysis in non-small cell lung cancer I Phillips, M Ajaz, V Ezhil, V Prakash, S Alobaidli, SJ McQuaid, C South, ... The British journal of radiology 91 (1081), 20170267, 2018 | 36 | 2018 |
| Stereotactic ablative body radiotherapy versus radical radiotherapy: comparing real-world outcomes in stage I lung cancer I Phillips, S Sandhu, M Lüchtenborg, S Harden Clinical Oncology 31 (10), 681-687, 2019 | 30 | 2019 |
| Comprehensive geriatric assessment in 326 older women with early breast cancer DO Okonji, R Sinha, I Phillips, D Fatz, A Ring British journal of cancer 117 (7), 925-931, 2017 | 29 | 2017 |
| Normal tissue complication probability (NTCP) modelling of severe acute mucositis using a novel oral mucosal surface organ at risk JA Dean, LC Welsh, KH Wong, A Aleksic, E Dunne, MR Islam, A Patel, ... Clinical oncology 29 (4), 263-273, 2017 | 28 | 2017 |
| Aspirin as a treatment for cancer I Phillips, R Langley, D Gilbert, A Ring Clinical Oncology 25 (6), 333-335, 2013 | 24 | 2013 |
| Androgen deprivation therapy and the re-emergence of parenteral estrogen in prostate cancer I Phillips, SIA Shah, T Duong, P Abel, RE Langley Oncology & hematology review 10 (1), 42, 2014 | 21 | 2014 |
| Biomarkers of systemic inflammation predict survival with first-line immune checkpoint inhibitors in non-small-cell lung cancer M Stares, TE Ding, C Stratton, F Thomson, M Baxter, H Cagney, ... ESMO open 7 (2), 100445, 2022 | 20 | 2022 |
| Assessment of fully-automated atlas-based segmentation of novel oral mucosal surface organ-at-risk JA Dean, LC Welsh, D McQuaid, KH Wong, A Aleksic, E Dunne, MR Islam, ... Radiotherapy and Oncology 119 (1), 166-171, 2016 | 16 | 2016 |
| Hypoalbuminaemia as a prognostic biomarker of first-line treatment resistance in metastatic non-small cell lung cancer M Stares, A Swan, K Cumming, TE Ding, J Leach, C Stratton, F Thomson, ... Frontiers in Nutrition 8, 734735, 2021 | 11 | 2021 |
| The stability of imaging biomarkers in radiomics: a framework for evaluation HYC Wang, EM Donovan, A Nisbet, CP South, S Alobaidli, V Ezhil, ... Physics in Medicine & Biology 64 (16), 165012, 2019 | 9 | 2019 |
| Nutritional status and symptom burden in advanced non-small cell lung cancer: results of the dietetic assessment and intervention in lung cancer (DAIL) trial I Phillips, L Allan, A Hug, N Westran, C Heinemann, M Hewish, A Mehta, ... BMJ supportive & palliative care 13 (e1), e213-e219, 2023 | 8 | 2023 |
| Prehabilitation services for people diagnosed with cancer in Scotland–Current practice, barriers and challenges to implementation D Provan, G McLean, SJ Moug, I Phillips, AS Anderson The Surgeon 20 (5), 284-290, 2022 | 8 | 2022 |
| Dietetic assessment and intervention in lung cancer I Phillips, A Hug, L Allan, V Ezhil Current Opinion in Supportive and Palliative Care 13 (4), 311-315, 2019 | 6 | 2019 |
| Optimising patient fitness: strategies to reduce the effects of cancer cachexia in patients with advanced lung cancer I Phillips, S Kestenbaum Current Opinion in Supportive and Palliative Care 14 (4), 304-308, 2020 | 3 | 2020 |
| Symptom burden strongly correlates with the need for a dietitian in advanced NSCLC I Philips, L Allan, A Hug, N Westram, C Heinemann, M Hewish, A Mehta, ... Annual BTOG/Lung Cancer, 2020 | 3 | 2020 |
| Rate of cachexia in lung cancer A Hug, I Phillips, L Allan, V Ezhil European Journal of Surgical Oncology 42 (11), S227, 2016 | 3 | 2016 |
| Early mortality following radiotherapy–meeting standards and improving patient selection. A Lerner, I Phillips, V Ezhil Clinical Oncology 27, S5-S6, 2015 | 3 | 2015 |
| Optimising outcomes in non small cell lung cancer: targeting cancer cachexia I Phillips, M Stares, L Allan, J Sayers, R Skipworth, B Laird Frontiers in Bioscience-Landmark 27 (4), 129, 2022 | 2 | 2022 |
| Early dietitian referral in lung cancer: use of machine learning M Chung, I Phillips, L Allan, N Westran, A Hug, PM Evans BMJ Supportive & Palliative Care, 2022 | 2 | 2022 |
| Scottish Immunotherapy Prognostic Score: biomarker of systemic inflammation predicts response to first-line pembrolizumab for metastatic non-small cell lung cancer TG Ding, F Thomson, C Stratton, K Cumming, C Barrie, K Maclennan, ... Lung Cancer 156, S43, 2021 | 2 | 2021 |
Mark StaresCancer Research UK Edinburgh CentreVerified email at ed.ac.uk
